| TRIAL |
PRODUCT |
CLADE |
CANDIDATE |
START |
END |
COUNTRIES |
NUMBER OF VOLUNTEERS |
PHASE |
IMMUNE RESPONSE |
RESULT |
| VAX003 |
AIDSVAX |
B/E |
Recombinant gp120 Protein |
1998 |
2003 |
Canada, Netherlands, Puerto Rico, US |
5,417 |
III |
T cell, Antibodies |
No Efficacy |
| VAX004 |
AIDSVAX |
B/E |
Recombinant gp120 Protein |
1998 |
2003 |
Thailand |
2,546 |
III |
T cell, Antibodies |
No Efficacy |
| STEP |
MRK-Ad5 |
B |
Ad5 gag/pol/nef |
2005 |
2007 |
Australia, Brazil, Canada, Dominican Republic, Haiti, Jamaica, Peru, Puerto Rico, USA |
3,000 |
IIb |
T cell |
No Efficacy |
| PHAMBILI |
MRK-Ad5 |
B |
Ad5 gag/pol/nef |
2005 |
2007 |
South Africa |
801 |
IIb |
T cell |
No Efficacy |
| RV144 |
ALVAC-HIV and AIDSVAX |
B/E |
Recombinant gp120 Protein + Canary pox vector |
2003 |
2009 |
Thailand |
16,402 |
III |
T cell, Antibodies |
31.20% |
| HVTN 505 |
DNA and Ad5 |
A/B/C |
DNA Ad5 gag/pol/nef |
2009 |
2013 |
USA |
2,500 |
IIb |
T cell, Antibodies |
No Efficacy |
|
